RS65595B1 - Antitela koja vezuju cd3 - Google Patents
Antitela koja vezuju cd3Info
- Publication number
- RS65595B1 RS65595B1 RS20240647A RSP20240647A RS65595B1 RS 65595 B1 RS65595 B1 RS 65595B1 RS 20240647 A RS20240647 A RS 20240647A RS P20240647 A RSP20240647 A RS P20240647A RS 65595 B1 RS65595 B1 RS 65595B1
- Authority
- RS
- Serbia
- Prior art keywords
- amino acid
- seq
- domain
- acid sequence
- bispecific antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394360P | 2016-09-14 | 2016-09-14 | |
| US201762491908P | 2017-04-28 | 2017-04-28 | |
| EP22159278.5A EP4050034B1 (en) | 2016-09-14 | 2017-06-20 | Cd3 binding antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65595B1 true RS65595B1 (sr) | 2024-06-28 |
Family
ID=61619675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240647A RS65595B1 (sr) | 2016-09-14 | 2017-06-20 | Antitela koja vezuju cd3 |
Country Status (33)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230129583A (ko) * | 2016-06-21 | 2023-09-08 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| EP4050034B1 (en) * | 2016-09-14 | 2024-05-08 | TeneoOne, Inc. | Cd3 binding antibodies |
| KR102633423B1 (ko) | 2016-12-21 | 2024-02-06 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| CA3067584A1 (en) * | 2017-06-20 | 2018-12-27 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
| US11427642B2 (en) * | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| EP3728319A1 (en) | 2017-12-22 | 2020-10-28 | TeneoBio, Inc. | Heavy chain antibodies binding to cd22 |
| KR20200104364A (ko) * | 2017-12-27 | 2020-09-03 | 테네오바이오, 인코포레이티드 | Cd3-델타/엡실론 이형이량체 특이적 항체 |
| PT3802608T (pt) | 2018-05-24 | 2025-06-27 | Janssen Biotech Inc | Anticorpos anti-cd3 e utilizações destes |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| SMT202400102T1 (it) | 2018-07-19 | 2024-05-14 | Regeneron Pharma | Recettori chimerici dell’antigene con specificità per bcma e loro usi |
| JP7439046B2 (ja) | 2018-07-20 | 2024-02-27 | テネオツー・インコーポレイテッド | Ｃｄ１９に結合する重鎖抗体 |
| US10867104B2 (en) * | 2018-08-31 | 2020-12-15 | Taiwan Semiconductor Manufacturing Company Ltd. | Isolation circuit between power domains |
| WO2020087065A1 (en) | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| KR20210149076A (ko) | 2019-04-05 | 2021-12-08 | 테네오바이오, 인코포레이티드 | Psma에 결합하는 중쇄 항체 |
| BR112021024956A2 (pt) * | 2019-06-14 | 2022-01-25 | Teneobio Inc | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 |
| EP3986932A1 (en) * | 2019-06-21 | 2022-04-27 | Università Degli Studi Magna Graecia Catanzaro | Monoclonal antibody targeting a unique cancer-associated epitope of cd43 |
| US20230374130A1 (en) * | 2019-07-30 | 2023-11-23 | Qlsf Biotherapeutics, Inc. | Bispecific anti lrrc15 and cd3epsilon antibodies |
| CN112574308A (zh) * | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
| JP2023507120A (ja) | 2019-12-18 | 2023-02-21 | テネオフォー， インコーポレイテッド | Ｃｄ３８に結合する重鎖抗体 |
| EP4142791A1 (en) | 2020-04-29 | 2023-03-08 | TeneoOne, Inc. | Methods of treating multiple myeloma |
| IL297644A (en) | 2020-04-29 | 2022-12-01 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| CA3214992A1 (en) | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| MX2022014938A (es) | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas. |
| PE20230464A1 (es) | 2020-06-30 | 2023-03-14 | Teneobio Inc | Union de anticuerpos multiespecificos a bcma |
| AU2021345124A1 (en) | 2020-09-16 | 2023-03-30 | Amgen Inc. | Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer |
| EP3991796A1 (en) * | 2020-10-27 | 2022-05-04 | Lindis Blood Care GmbH | An ex vivo method for removal of tumor cells from intra-operatively salvaged blood |
| TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| CA3211138A1 (en) | 2021-02-25 | 2022-09-01 | Teneobio, Inc. | Anti-psma antibodies and car-t structures |
| KR20230150825A (ko) | 2021-02-26 | 2023-10-31 | 테네오바이오, 인코포레이티드 | 항-muc1-c 항체 및 car-t 구조 |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| KR20230166090A (ko) | 2021-04-06 | 2023-12-06 | 테네오바이오, 인코포레이티드 | 항-cd19 항체 및 car-t 구조체 |
| IL306045A (en) | 2021-04-16 | 2023-11-01 | Teneobio Inc | Anti-cd20 antibodies and car-t structures |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| CN119569887A (zh) * | 2021-06-24 | 2025-03-07 | 益科思特(北京)医药科技发展有限公司 | 结合bcma和cd3的双特异性抗体及其制备方法与应用 |
| US20240376156A1 (en) * | 2021-07-13 | 2024-11-14 | University Of Washington | Multiple de novo designed protein binding proteins |
| WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
| MX2024001761A (es) | 2021-08-09 | 2024-04-29 | Harbour Biomed Shanghai Co Ltd | Anticuerpo dirigido contra cldn18.2, anticuerpo biespecífico y el uso de estos. |
| MX2024004550A (es) | 2021-10-14 | 2024-04-29 | Teneobio Inc | Proteinas de union a la mesotelina y usos de las mismas. |
| WO2024026358A1 (en) | 2022-07-27 | 2024-02-01 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
| AU2023356984A1 (en) | 2022-10-05 | 2025-03-20 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
| WO2024178056A1 (en) | 2023-02-21 | 2024-08-29 | Teneobio, Inc. | C-kit binding proteins, chimeric antigen receptors, and uses thereof |
| KR20240139569A (ko) * | 2023-03-13 | 2024-09-23 | 머스트바이오 주식회사 | 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025217101A2 (en) | 2024-04-09 | 2025-10-16 | Amgen Inc. | Agonistic anti-il-2rbg heavy‑chain antibodies |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025235357A1 (en) | 2024-05-06 | 2025-11-13 | Rondo Therapeutics, Inc. | Bispecific antibodies that bind to cd28 and nectin-4 |
| WO2025245399A1 (en) | 2024-05-23 | 2025-11-27 | Indapta Therapeutics, Inc. | Method of treating cancer with natural killer cells |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| US5968509A (en) | 1990-10-05 | 1999-10-19 | Btp International Limited | Antibodies with binding affinity for the CD3 antigen |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6037453A (en) * | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| DE69830901T2 (de) | 1997-05-02 | 2006-05-24 | Genentech Inc., San Francisco | ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| WO2000040716A2 (en) | 1999-01-07 | 2000-07-13 | Zymogenetics, Inc. | Soluble receptor br43x2 and methods of using them for therapy |
| WO2001012812A2 (en) | 1999-08-17 | 2001-02-22 | Biogen, Inc. | Baff receptor (bcma), an immunoregulatory agent |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| US20020004587A1 (en) | 2000-04-11 | 2002-01-10 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| ATE361318T1 (de) | 2000-05-12 | 2007-05-15 | Amgen Inc | Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen |
| MXPA03005944A (es) * | 2000-12-29 | 2005-04-29 | Bio Technology General Corp | Anticuerpos humanos especificos para terapia selectiva de cancer. |
| EP1362061A2 (en) | 2001-02-20 | 2003-11-19 | ZymoGenetics, Inc. | Antibodies that bind both bcma and taci |
| CN1195779C (zh) | 2001-05-24 | 2005-04-06 | 中国科学院遗传与发育生物学研究所 | 抗人卵巢癌抗人cd3双特异性抗体 |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| EP1578447A4 (en) | 2002-10-31 | 2009-06-03 | Genentech Inc | METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| US7919089B2 (en) | 2003-05-31 | 2011-04-05 | Micromet Ag | Pharmaceutical composition comprising a bispecific antibody for EpCAM |
| RU2401843C2 (ru) | 2003-10-16 | 2010-10-20 | Микромет Аг | Полиспецифические деиммунизирующие cd3-связующие |
| PL2383295T3 (pl) * | 2003-12-10 | 2015-08-31 | Squibb & Sons Llc | IP-10 przeciwciała i ich zastosowanie |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| SG155883A1 (en) | 2004-06-03 | 2009-10-29 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| WO2006008548A2 (en) | 2004-07-22 | 2006-01-26 | Erasmus University Medical Centre Rotterdam | Binding molecules |
| EP1848745B1 (en) | 2005-02-18 | 2014-07-09 | Medarex, L.L.C. | Monoclonal antibodies against cd30 lacking in fucosyl residues |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| EP1909831A4 (en) | 2005-06-14 | 2013-02-20 | Amgen Inc | SELF-BUFFING PROTEIN FORMULATIONS |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20100209437A1 (en) | 2005-09-12 | 2010-08-19 | Greg Elson | Anti-CD3 Antibody Fromulations |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| JP2009511032A (ja) * | 2005-10-11 | 2009-03-19 | アブリンクス エン．ヴェー． | Ｅｇｆｒおよびｉｇｆ−ｉｒに対するナノボディおよびポリペプチド |
| EP1957099B1 (en) | 2005-11-07 | 2015-03-25 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| JP6088723B2 (ja) | 2005-11-23 | 2017-03-01 | ジェネンテック， インコーポレイテッド | Ｂ細胞アッセイに関する組成物及び方法。 |
| TW200738750A (en) | 2005-12-06 | 2007-10-16 | Domantis Ltd | Ligands and methods of use therefor |
| JP6084761B2 (ja) | 2006-04-05 | 2017-02-22 | ザ ロックフェラー ユニバーシティー | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
| US7862813B2 (en) | 2006-07-29 | 2011-01-04 | Bjork Jr Robert Lamar | Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug |
| KR20090088852A (ko) * | 2006-09-05 | 2009-08-20 | 메다렉스, 인코포레이티드 | 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법 |
| MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
| EP4059964A1 (en) | 2007-04-03 | 2022-09-21 | Amgen Research (Munich) GmbH | Cross-species-specific binding domain |
| EP2155783B2 (en) | 2007-04-03 | 2022-10-19 | Amgen Research (Munich) GmbH | Cross-species-specific cd3-epsilon binding domain |
| DK2152880T3 (da) | 2007-06-01 | 2011-11-28 | Omt Inc | Sammensætninger og fremgangsmåder til hæmning af endogene immunoglobulingener og produktion af transgene, humane idiotype antistoffer |
| WO2009132058A2 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| HUE030090T2 (en) * | 2008-10-01 | 2017-04-28 | Amgen Res Munich Gmbh | Cross-species-specific psmaxcd3 bispecific single chain antibody |
| CA2738566C (en) | 2008-10-01 | 2024-04-30 | Micromet Ag | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| WO2010037835A2 (en) | 2008-10-01 | 2010-04-08 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| NZ612647A (en) | 2009-03-10 | 2015-03-27 | Biogen Idec Inc | Anti-bcma antibodies |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| ME02288B (me) | 2010-02-08 | 2016-02-20 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| US20130273055A1 (en) * | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
| WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
| EP2683735A1 (en) | 2011-03-10 | 2014-01-15 | HCO Antibody, Inc. | Bispecific three-chain antibody-like molecules |
| US20130101599A1 (en) | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| SG194176A1 (en) | 2011-05-27 | 2013-12-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| HK1208707A1 (en) * | 2012-04-20 | 2016-03-11 | 阿帕特夫研究和发展有限公司 | Cd3 binding polypeptides |
| BR112014032916A2 (pt) * | 2012-06-28 | 2017-08-01 | Pfizer | anticorpos anti-fármacos e usos destes para o monitoramento de fármaco |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US10002206B2 (en) | 2012-10-26 | 2018-06-19 | Saturn Licensing Llc | Information processing device and information processing method |
| CA2889764C (en) | 2012-11-01 | 2023-10-10 | Martin Lipp | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| ES2813609T5 (es) | 2012-12-14 | 2024-08-09 | Omniab Inc | Polinucleótidos que codifican anticuerpos de roedores con idiotipos humanos y animales que los contienen |
| CN104968682A (zh) | 2013-02-05 | 2015-10-07 | 英格玛布股份公司 | 针对CD3ε和BCMA的双特异性抗体 |
| EP2762496A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| TW201522378A (zh) | 2013-10-31 | 2015-06-16 | Sanofi Sa | 用於治療人類癌症的特異性抗ｃｄ３８抗體 |
| CN105873953A (zh) | 2013-11-04 | 2016-08-17 | 格兰马克药品股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| WO2015095412A1 (en) * | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| US10106623B2 (en) | 2014-02-12 | 2018-10-23 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| SI3122781T1 (sl) | 2014-03-28 | 2020-03-31 | Xencor, Inc. | Bispecifična protitelesa, ki se vežejo na CD38 in CD3 |
| RU2751660C2 (ru) | 2014-07-21 | 2021-07-15 | Новартис Аг | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма |
| AU2015292406B2 (en) * | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
| ES2701061T5 (es) | 2014-10-22 | 2022-05-09 | Crescendo Biologics Ltd | Ratones transgénicos |
| EP3023437A1 (en) * | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| HRP20201156T1 (hr) * | 2014-11-20 | 2020-11-13 | F. Hoffmann - La Roche Ag | Zajednički laki lanci i postupci primjene |
| JP6671370B2 (ja) | 2014-12-12 | 2020-03-25 | ブルーバード バイオ， インコーポレイテッド | Ｂｃｍａキメラ抗原受容体 |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| GB201500461D0 (en) | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
| EP3056512A1 (en) * | 2015-02-10 | 2016-08-17 | Medizinische Universität Wien | Antibody construct |
| CN106211261B (zh) | 2015-04-10 | 2020-10-16 | 中兴通讯股份有限公司 | 信息处理方法及通信节点 |
| KR102602754B1 (ko) | 2015-05-20 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체 |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| IL320478A (en) | 2015-08-17 | 2025-06-01 | Janssen Biotech Inc | Anti-BCMA antibodies, bispecific antigen-binding molecules that bind BCMA and CD3, and uses thereof |
| EP3374397A2 (en) | 2015-11-10 | 2018-09-19 | University Medical Center Hamburg - Eppendorf | Antigen-binding polypeptides directed against cd38 |
| KR20230129583A (ko) | 2016-06-21 | 2023-09-08 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| KR102702078B1 (ko) | 2016-08-24 | 2024-09-04 | 테네오바이오, 인코포레이티드 | 변형된 중쇄-단독 항체를 생산하는 형질전환 비-인간 동물 |
| EP4050034B1 (en) * | 2016-09-14 | 2024-05-08 | TeneoOne, Inc. | Cd3 binding antibodies |
| KR102633423B1 (ko) | 2016-12-21 | 2024-02-06 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| CA3067584A1 (en) | 2017-06-20 | 2018-12-27 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
| JP7288405B2 (ja) | 2017-06-30 | 2023-06-07 | アメリカ合衆国 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| EP3728319A1 (en) | 2017-12-22 | 2020-10-28 | TeneoBio, Inc. | Heavy chain antibodies binding to cd22 |
| KR20200104364A (ko) * | 2017-12-27 | 2020-09-03 | 테네오바이오, 인코포레이티드 | Cd3-델타/엡실론 이형이량체 특이적 항체 |
| MX2020012561A (es) * | 2018-05-24 | 2021-01-29 | Ayala Pharmaceuticals Inc | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiazepinona e inmunoterapeuticos y metodos de uso de las mismas. |
| JP7439046B2 (ja) | 2018-07-20 | 2024-02-27 | テネオツー・インコーポレイテッド | Ｃｄ１９に結合する重鎖抗体 |
| CA3113057A1 (en) | 2018-09-21 | 2020-03-26 | Teneobio, Inc. | Methods for purifying heterodimeric, multispecific antibodies |
| WO2020087065A1 (en) | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
| KR20210149076A (ko) | 2019-04-05 | 2021-12-08 | 테네오바이오, 인코포레이티드 | Psma에 결합하는 중쇄 항체 |
| BR112021024956A2 (pt) * | 2019-06-14 | 2022-01-25 | Teneobio Inc | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 |
| IL297644A (en) | 2020-04-29 | 2022-12-01 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| CA3214992A1 (en) | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| EP4142791A1 (en) | 2020-04-29 | 2023-03-08 | TeneoOne, Inc. | Methods of treating multiple myeloma |
| US20220235380A1 (en) * | 2021-01-26 | 2022-07-28 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| MX2024004550A (es) * | 2021-10-14 | 2024-04-29 | Teneobio Inc | Proteinas de union a la mesotelina y usos de las mismas. |
-
2017
- 2017-06-20 EP EP22159278.5A patent/EP4050034B1/en active Active
- 2017-06-20 MX MX2019002967A patent/MX2019002967A/es unknown
- 2017-06-20 CR CR20220578A patent/CR20220578A/es unknown
- 2017-06-20 KR KR1020257018726A patent/KR20250088655A/ko active Pending
- 2017-06-20 DK DK22159278.5T patent/DK4050034T3/da active
- 2017-06-20 MY MYPI2022002552A patent/MY200988A/en unknown
- 2017-06-20 IL IL290517A patent/IL290517B2/en unknown
- 2017-06-20 SI SI201731524T patent/SI4050034T1/sl unknown
- 2017-06-20 CA CA3036550A patent/CA3036550A1/en active Pending
- 2017-06-20 CR CR20220408A patent/CR20220408A/es unknown
- 2017-06-20 KR KR1020197010099A patent/KR102505681B1/ko active Active
- 2017-06-20 CN CN201780062822.4A patent/CN109843325B/zh active Active
- 2017-06-20 CN CN202210150122.3A patent/CN114395048B/zh active Active
- 2017-06-20 KR KR1020227006672A patent/KR102507537B1/ko active Active
- 2017-06-20 CN CN202311092843.4A patent/CN117603353A/zh active Pending
- 2017-06-20 KR KR1020237007421A patent/KR20230035706A/ko not_active Ceased
- 2017-06-20 AU AU2017327723A patent/AU2017327723B2/en active Active
- 2017-06-20 RS RS20240647A patent/RS65595B1/sr unknown
- 2017-06-20 PT PT221592785T patent/PT4050034T/pt unknown
- 2017-06-20 JP JP2019514099A patent/JP7030109B2/ja active Active
- 2017-06-20 IL IL313895A patent/IL313895A/en unknown
- 2017-06-20 EP EP17851217.4A patent/EP3512549A4/en active Pending
- 2017-06-20 FI FIEP22159278.5T patent/FI4050034T3/fi active
- 2017-06-20 PL PL22159278.5T patent/PL4050034T3/pl unknown
- 2017-06-20 PE PE2024000894A patent/PE20241349A1/es unknown
- 2017-06-20 UA UAA201903677A patent/UA126384C2/uk unknown
- 2017-06-20 US US16/332,665 patent/US11505606B2/en active Active
- 2017-06-20 HR HRP20240767TT patent/HRP20240767T1/hr unknown
- 2017-06-20 LT LTEP22159278.5T patent/LT4050034T/lt unknown
- 2017-06-20 BR BR112019004873A patent/BR112019004873A2/pt unknown
- 2017-06-20 IL IL265321A patent/IL265321B2/en unknown
- 2017-06-20 HU HUE22159278A patent/HUE066651T2/hu unknown
- 2017-06-20 WO PCT/US2017/038377 patent/WO2018052503A1/en not_active Ceased
- 2017-06-20 NZ NZ752294A patent/NZ752294A/en unknown
- 2017-06-20 PE PE2019000520A patent/PE20190976A1/es unknown
- 2017-06-20 ES ES22159278T patent/ES2980623T3/es active Active
- 2017-06-20 CR CR20190198A patent/CR20190198A/es unknown
- 2017-06-20 KR KR1020247009294A patent/KR20240044520A/ko not_active Ceased
- 2017-06-20 BR BR122022002481A patent/BR122022002481A8/pt unknown
- 2017-06-20 EP EP24172651.2A patent/EP4417263A3/en active Pending
-
2019
- 2019-03-13 PH PH12019500545A patent/PH12019500545A1/en unknown
- 2019-03-13 MX MX2022002018A patent/MX2022002018A/es unknown
- 2019-03-13 CL CL2019000643A patent/CL2019000643A1/es unknown
- 2019-03-13 SA SA523442262A patent/SA523442262B1/ar unknown
- 2019-03-13 DO DO2019000059A patent/DOP2019000059A/es unknown
- 2019-03-13 MX MX2024011616A patent/MX2024011616A/es unknown
- 2019-03-13 SA SA522431672A patent/SA522431672B1/ar unknown
- 2019-03-13 MX MX2024011615A patent/MX2024011615A/es unknown
- 2019-04-12 CO CONC2019/0003706A patent/CO2019003706A2/es unknown
- 2019-04-12 EC ECSENADI201926304A patent/ECSP19026304A/es unknown
-
2021
- 2021-10-01 US US17/492,444 patent/US11421027B2/en active Active
- 2021-12-09 CL CL2021003289A patent/CL2021003289A1/es unknown
- 2021-12-09 CL CL2021003290A patent/CL2021003290A1/es unknown
-
2022
- 2022-01-04 JP JP2022000116A patent/JP7321303B2/ja active Active
- 2022-01-04 JP JP2022000115A patent/JP7431868B2/ja active Active
- 2022-02-24 AU AU2022201278A patent/AU2022201278B2/en active Active
- 2022-03-18 ZA ZA2022/03250A patent/ZA202203250B/en unknown
- 2022-08-19 US US17/821,143 patent/US20230082151A1/en not_active Abandoned
- 2022-10-03 US US17/937,750 patent/US20230272075A1/en not_active Abandoned
- 2022-10-27 DO DO2022000233A patent/DOP2022000233A/es unknown
- 2022-12-26 CL CL2022003769A patent/CL2022003769A1/es unknown
-
2023
- 2023-07-25 JP JP2023120345A patent/JP2023156342A/ja active Pending
- 2023-08-24 DO DO2023000165A patent/DOP2023000165A/es unknown
- 2023-11-08 JP JP2023190749A patent/JP7521729B2/ja active Active
- 2023-11-08 JP JP2023190748A patent/JP7521728B2/ja active Active
-
2024
- 2024-07-10 JP JP2024110717A patent/JP2024153676A/ja active Pending
-
2025
- 2025-03-24 US US19/088,689 patent/US20250340638A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7521729B2 (ja) | Ｃｄ３結合抗体 | |
| US20240018235A1 (en) | Cd3 binding antibodies | |
| RU2807216C2 (ru) | Антитела, связывающие cd3 | |
| HK40107381A (en) | Cd3 binding antibodies | |
| RU2790288C2 (ru) | Антитела, связывающие cd3 | |
| HK40078017A (en) | Cd3 binding antibodies | |
| HK40078017B (en) | Cd3 binding antibodies | |
| KR20250175345A (ko) | Cd3 결합 항체 |